NCT05697146 2026-03-16
RosaLEE
Novartis
Active not recruiting
Clinical Trials
18 trialsNCT06930859 2026-03-16
ELEGANCE
Novartis
Recruiting
NCT06830720 2026-03-03
CAROLEEN
Novartis
Recruiting
NCT06905301 2026-02-20
IMPULSE
Novartis
Recruiting
NCT06797531 2026-02-04
NISLEESA
Novartis
Recruiting
NCT04943497 2025-12-09
PROSPERITY
Novartis
Completed
NCT06148506 2025-12-05
ValerEE
Novartis
Active not recruiting
NCT06495164 2025-11-25
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
Pfizer
Active not recruiting
NCT07072013 2025-07-18
IRINA
Novartis
Completed
NCT07008508 2025-06-06
BRAVE-Cyclin
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Active not recruiting
NCT06805812 2025-02-03
PALMARES-2
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Recruiting
NCT06075758 2025-01-14
A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer
Novartis
Recruiting
NCT06587789 2024-11-21
Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting
NCT06367335 2024-04-16
ETIC
University of Milano Bicocca
Completed
NCT05569187 2022-11-08
Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer
Novartis
Completed
NCT05153135 2021-12-21
Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors
Novartis
Completed
NCT05051956 2021-09-21
Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?
Namik Kemal University
Unknown
NCT04852081 2021-04-21
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
Blokhin's Russian Cancer Research Center
Unknown